RASONQUE (Daraxonrasib) Patent Expiration, LOE Window & CMS Spending

RASONQUE (Daraxonrasib) by Revolution Medicines: FDA Orange Book core substance LOE 2042-01-24, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $19,900 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRevolution Medicines
FDA Application & PathwayN220910 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2042-01-24
Last Listed Patent or Exclusivity Date2042-01-24
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($19,900 intro WAC)